2023
Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report
Lee T, Aisner D, David M, Eno C, Gagan J, Gocke C, Guseva N, Haley L, Jajosky A, Jones D, Mansukhani M, Mroz P, Murray S, Newsom K, Paulson V, Roy S, Rushton C, Segal J, Senaratne T, Siddon A, Starostik P, Van Ziffle J, Wu D, Xian R, Yohe S, Kim A. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Advances 2023, 7: 4599-4607. PMID: 37236162, PMCID: PMC10425685, DOI: 10.1182/bloodadvances.2023010149.Peer-Reviewed Original ResearchConceptsMolecular testingAcute casesHematologic malignanciesRapid turnaround timeTertiary care laboratoryAcute myeloid leukemiaCurrent clinical practiceMyeloid leukemiaTurnaround timeLymphoid processesClinical practicePatient careNGS panelCalendar daysClinical expectationsWorking Group ReportMost survey respondentsMalignancyCareReimbursementCase reimbursementSurvey respondentsGroup ReportTesting practicesDaysMolecular findings in myeloid neoplasms
Tran T, Siddon A. Molecular findings in myeloid neoplasms. International Journal Of Laboratory Hematology 2023, 45: 442-448. PMID: 37345257, DOI: 10.1111/ijlh.14118.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid neoplasmsNext-generation sequencingMyeloproliferative neoplasmsInternational diagnostic guidelinesSomatic gene mutationsHematologic cancersMyeloid leukemiaDiagnostic guidelinesClinical relevanceMyeloid disordersPatient careNeoplasmsCytogenetic findingsMolecular findingsGene mutationsNew molecular technologiesMolecular technologiesMutationsLeukemiaCancerPrognosticationCliniciansFindingsModifier mutations
2020
Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost
Gisriel S, Rinder H, Siddon A. Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost. Blood 2020, 136: 39-40. DOI: 10.1182/blood-2020-139035.Peer-Reviewed Original ResearchNext-generation sequencingNGS testingNGS testsAML/MDSEvidence-based indicationsPatients' emotional distressCancellation criteriaMedicaid Services reimbursementPersonalized patient careClinical suspicionPathologic diagnosisMedical recordsClinical indicationsClinical trialsChimerism statusUnnecessary testingMDS progressionPatient carePathogenic variantsMolecular findingsUnknown significancePatientsPathogenic mutationsService reimbursementMolecular diagnostic laboratories